Return-Path: <info@boxpacking.gr>
Delivered-To: govancoz@zacp120.webway.host
Received: from zacp120.webway.host
	by zacp120.webway.host with LMTP
	id QN4SEJxa62hxcQsA8rC0kQ
	(envelope-from <info@boxpacking.gr>)
	for <govancoz@zacp120.webway.host>; Sun, 12 Oct 2025 09:37:00 +0200
Return-path: <info@boxpacking.gr>
Envelope-to: cheryl@govan.co.za
Delivery-date: Sun, 12 Oct 2025 09:37:00 +0200
Received: from static.217.135.4.185.clients.grserver.gr ([185.4.135.217]:33316 helo=bioshop.gr)
	by zacp120.webway.host with esmtps  (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256
	(Exim 4.98.2)
	(envelope-from <info@boxpacking.gr>)
	id 1v7qdV-00000003JAL-2I1D
	for cheryl@govan.co.za;
	Sun, 12 Oct 2025 09:37:00 +0200
Received: from ws-dip-gc02.diplomat.com.mt (c155-179.i01-7.onvol.net [212.56.155.179])
	by bioshop.gr (Postfix) with ESMTPSA id 7BB306D9BE;
	Sat, 11 Oct 2025 21:45:29 +0300 (EEST)
Content-Type: multipart/alternative; boundary="===============1108606703=="
MIME-Version: 1.0
Subject: Proposal for Strategic Business Collaboration.
To: Recipients <info@boxpacking.gr>
From: "Dr. Shingo Iwamoto" <info@boxpacking.gr>
Date: Sat, 11 Oct 2025 20:45:19 +0200
Reply-To: drshingoiwamotopharm1@gmail.com
X-PPP-Message-ID: <20251011184535.24684.24496@bioshop.gr>
X-PPP-Vhost: boxpacking.gr
X-Spam-Status: No, score=2.0
X-Spam-Score: 20
X-Spam-Bar: ++
X-Ham-Report: =?ISO-8859-1?Q?Spam_detection_software=2C_running_on_the_system_=22zacp120=2Ewebway?= =?ISO-8859-1?Q?=2Ehost=22=2C=0A_has_NOT_identified_this_incoming_ema?= =?ISO-8859-1?Q?il_as_spam=2E__The_original=0A_message_has_been_attac?= =?ISO-8859-1?Q?hed_to_this_so_you_can_view_it_or_label=0A_similar_fu?= =?ISO-8859-1?Q?ture_email=2E__If_you_have_any_questions=2C_see=0A_ro?= =?ISO-8859-1?Q?ot=5C=40localhost_for_details=2E=0A_Content_preview=3A_?= =?ISO-8859-1?Q?_Dear_Esteemed_Professional=2C_I_hope_this_message_fi?= =?ISO-8859-1?Q?nds_you=0A___well=2E_Nichi-Iko_Pharmaceutical_Co=2E=2C?= =?ISO-8859-1?Q?_Ltd=2E=2C_a_leading_pharmaceutical_manufacturer=0A__?= =?ISO-8859-1?Q?__based_in_Japan=2C_is_currently_seeking_a_qualified_?= =?ISO-8859-1?Q?individual_to_=5B=2E=2E=2E=5D_=0A_Content_analysis_de?= =?ISO-8859-1?Q?tails=3A___=282=2E0_points=2C_5=2E0_required=29=0A__p?= =?ISO-8859-1?Q?ts_rule_name______________description=0A_----_-------?= =?ISO-8859-1?Q?---------------_-------------------------------------?= =?ISO-8859-1?Q?-------------=0A_-0=2E0_SPF=5FHELO=5FPASS__________SP?= =?ISO-8859-1?Q?F=3A_HELO_matches_SPF_record=0A_-0=2E0_SPF=5FPASS____?= =?ISO-8859-1?Q?___________SPF=3A_sender_matches_SPF_record=0A__0=2E0?= =?ISO-8859-1?Q?_KAM=5FDMARC=5FSTATUS_______Test_Rule_for_DKIM_or_SPF?= =?ISO-8859-1?Q?_Failure_with_Strict=0A_____________________________A?= =?ISO-8859-1?Q?lignment=0A__0=2E0_RCVD=5FIN=5FVALIDITY=5FCERTIFIED=5FB?= =?ISO-8859-1?Q?LOCKED_RBL=3A_ADMINISTRATOR_NOTICE=3A_The=0A_________?= =?ISO-8859-1?Q?____________________query_to_Validity_was_blocked=2E_?= =?ISO-8859-1?Q?_See=0A_____________________________https=3A//knowled?= =?ISO-8859-1?Q?ge=2Evalidity=2Ecom/hc/en-us/articles/20961730681243=0A_?= =?ISO-8859-1?Q?_____________________________for_more_information=2E=0A?= =?ISO-8859-1?Q?__________________________=5B185=2E4=2E135=2E217_list?= =?ISO-8859-1?Q?ed_in_sa-trusted=2Ebondedsender=2Eorg=5D=0A__0=2E0_RC?= =?ISO-8859-1?Q?VD=5FIN=5FVALIDITY=5FRPBL=5FBLOCKED_RBL=3A_ADMINISTRA?= =?ISO-8859-1?Q?TOR_NOTICE=3A_The_query_to=0A________________________?= =?ISO-8859-1?Q?______Validity_was_blocked=2E__See=0A________________?= =?ISO-8859-1?Q?_____________https=3A//knowledge=2Evalidity=2Ecom/hc/?= =?ISO-8859-1?Q?en-us/articles/20961730681243=0A_____________________?= =?ISO-8859-1?Q?_________for_more_information=2E=0A__________________?= =?ISO-8859-1?Q?___________=5B185=2E4=2E135=2E217_listed_in_bl=2Escor?= =?ISO-8859-1?Q?e=2Esenderscore=2Ecom=5D=0A__0=2E0_RCVD=5FIN=5FVALIDI?= =?ISO-8859-1?Q?TY=5FSAFE=5FBLOCKED_RBL=3A_ADMINISTRATOR_NOTICE=3A_Th?= =?ISO-8859-1?Q?e_query_to=0A______________________________Validity_w?= =?ISO-8859-1?Q?as_blocked=2E__See=0A_____________________________htt?= =?ISO-8859-1?Q?ps=3A//knowledge=2Evalidity=2Ecom/hc/en-us/articles/2?= =?ISO-8859-1?Q?0961730681243=0A______________________________for_mor?= =?ISO-8859-1?Q?e_information=2E=0A_____________________________=5B18?= =?ISO-8859-1?Q?5=2E4=2E135=2E217_listed_in_sa-accredit=2Ehabeas=2Eco?= =?ISO-8859-1?Q?m=5D=0A__0=2E2_FREEMAIL=5FREPLYTO=5FEND=5FDIGIT_Reply?= =?ISO-8859-1?Q?-To_freemail_username_ends_in_digit=0A_______________?= =?ISO-8859-1?Q?______________=5Bdrshingoiwamotopharm1=28at=29gmail=2Ec?= =?ISO-8859-1?Q?om=5D=0A__0=2E0_HTML=5FMESSAGE___________BODY=3A_HTML?= =?ISO-8859-1?Q?_included_in_message=0A__1=2E8_FREEMAIL=5FFORGED=5FRE?= =?ISO-8859-1?Q?PLYTO_Freemail_in_Reply-To=2C_but_not_From?=
X-Spam-Flag: NO

You will not see this in a MIME-aware mail reader.
--===============1108606703==
Content-Type: text/plain; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body

Dear Esteemed Professional,
 I hope this message finds you well.
 Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer =
based in Japan, is currently seeking a qualified individual to serve as our=
 official representative in South Africa. This role involves managing miner=
al procurement and overseeing the establishment of our annex office in Sout=
h Africa under a five-year contractual agreement.
 This is a strategic opportunity to represent a respected global brand and =
play a key role in expanding our international presence. We are offering a =
competitive compensation package along with decision-making autonomy.
 If you are interested in learning more, kindly respond to this message for=
 further details.
 Warm regards,
Dr. Shingo Iwamoto
President & CEO
Nichi-Iko Pharmaceutical Co., Ltd.
5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan

--===============1108606703==
Content-Type: text/html; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body

<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Diso-8859-1"/></head><BODY><P>Dear Esteemed Professional,</P>
<P>I hope this message finds you well.</P>
<P>Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacture=
r based in Japan, is currently seeking a qualified individual to serve as o=
ur official representative in South Africa. This role involves managing min=
eral procurement and overseeing the establishment of our annex office in So=
uth Africa under a five-year contractual agreement.</P>
<P>This is a strategic opportunity to represent a respected global brand an=
d play a key role in expanding our international presence. We are offering =
a competitive compensation package along with decision-making autonomy.</P>
<P>If you are interested in learning more, kindly respond to this message f=
or further details.</P>
<P>Warm regards,<BR>Dr. Shingo Iwamoto<BR>President &amp; CEO<BR>Nichi-Iko =
Pharmaceutical Co., Ltd.<BR>5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, =
Japan</P></BODY></HTML>
--===============1108606703==--